Geographic atrophy can be challenging to deal with at times, but it’s not impossible. A low-vision ophthalmologist shares how she helps people with the condition live their best lives.

Staff Sgt. Ryan Voss, explosive ordnance disposal technician with Kosovo Force Regional-Command East EOD, briefs Chief Warrant Officer 3 Elisa Locke, 2nd Battalion, 135th General Support Aviation ...

Pegcetacoplan, an investigational complement factor inhibitor that has the potential to be the first FDA–approved treatment for geographic atrophy in dry age-related macular degeneration (AMD ...

Purpose: X-linked infantile spinal-muscular atrophy (XL-SMA) is a rare disorder, which presents with the clinical characteristics of hypotonia, areflexia, and multiple congenital contractures ...

Zhou C, Guan XJ, Guo T, et al. Progressive brain atrophy in Parkinson’s disease patients who convert to mild cognitive impairment [published online July 6, 2019]. CNS Neurosci Ther . doi: 10. ...

Muscle atrophy is characterized by the gradual weakening and wasting away of muscle tissues. This condition can be triggered by factors such as insufficient muscle use, malnutrition, diseases, or ...

Access free, up-to-date clinical references for a comprehensive overview on the epidemiology and risk of factors for geographic atrophy. Healio's Clinical Guidance content provides valuable ...

SACRAMENTO, Calif. (Dec. 18, 2013) -- Capt. Shannon Terry and her husband, Randall, started to notice some irregularities in their beautiful baby girl Reagan just a few months after her birth ...

September 27, 2011 — A new study provides more evidence that poor vitamin B12 status is a risk factor for brain atrophy and cognitive impairment, and highlights the importance of vitamin B12 ...

We identify the atrophy with OCT using the cRORA definition, and then we measure the atrophy on FAF and adjunctive technology, such as OCT, NIR and FA,” Jaffe said.

When it was approved, Zolgensma carried a list price of $2.1 million, compared with Spinraza’s list price of about $750,000 for the first year of treatment and $375,000 annually per subsequent year.